Literature DB >> 2870720

Pharmacodynamic profile of the selective beta 1-adrenoceptor antagonist bisoprolol.

J Harting, K H Becker, R Bergmann, R Bourgois, H J Enenkel, A Fuchs, R Jonas, H Lettenbaur, K O Minck, P Schelling.   

Abstract

The pharmacodynamic activity of (+/-)-1-[4-(2-isopropoxyethoxymethyl)-phenoxy]-3-isopropylamino-2- propranol- hemifumarate (bisoprolol, EMD 33 512) has been investigated under in vitro and in vivo conditions. Bisoprolol was found to be an effective beta-adrenoceptor antagonist, the pA2 values determined against isoprenaline in guinea pig atria and tracheal muscle being 7.45 and 6.41, respectively. Thus, the selectivity ratio of bisoprolol in favour of beta 1-adrenoceptors is 11. Inhibition of the isoprenaline-induced tachycardia in guinea pigs indicated a long duration of action for bisoprolol. The compound was devoid of intrinsic sympathomimetic activity as shown by the lack of effect on heart rate in anaesthetized and reserpine pretreated rats. Studies in rabbits and guinea pigs revealed a local anaesthetic activity of bisoprolol at high concentrations. Bisoprolol protected the hearts of anaesthetized dogs against the sequelae of intermittent coronary occlusions, as judged by the reduction of the ST-segment elevation in the epicardial ECG. Bisoprolol exerted a blood pressure lowering effect in conscious renal hypertensive dogs after oral administration of 30 micrograms/kg. There was no indication of any action on the CNS in monkeys following an oral dose of up to 8 mg/kg.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2870720

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  6 in total

Review 1.  Bisoprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris.

Authors:  S G Lancaster; E M Sorkin
Journal:  Drugs       Date:  1988-09       Impact factor: 9.546

2.  Hemodynamic evaluation of bisoprolol after coronary artery surgery in patients with altered left ventricular function.

Authors:  M Goldstein; J L Vincent; J L Le Clerc; A d'Hollander; C Melot; R J Kahn
Journal:  Cardiovasc Drugs Ther       Date:  1991-06       Impact factor: 3.727

3.  Microbial metabolism of the beta-adrenoreceptor antagonist bisoprolol.

Authors:  H Schwartz; R E Licht; H E Radunz
Journal:  Appl Microbiol Biotechnol       Date:  1993-11       Impact factor: 4.813

4.  Bisoprolol improves perfusion of ischaemic myocardium in anaesthetized pigs.

Authors:  L M Sassen; M O den Boer; R J Rensen; P R Saxena; P D Verdouw
Journal:  Br J Pharmacol       Date:  1988-10       Impact factor: 8.739

5.  Efficacy and tolerability of a β-1 selective β blocker, bisoprolol, as a first-line antihypertensive in Indian patients diagnosed with essential hypertension (BRIGHT): an open-label, multicentric observational study.

Authors:  V Channaraya; R K Marya; M Somasundaram; Debashish Mitra; K D Tibrewala
Journal:  BMJ Open       Date:  2012-05-14       Impact factor: 2.692

6.  Model-based meta-analysis of changes in circulatory system physiology in patients with chronic heart failure.

Authors:  Ryota Takaoka; Yukako Soejima; Sayuri Guro; Hideki Yoshioka; Hiromi Sato; Hiroshi Suzuki; Akihiro Hisaka
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-07-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.